HR and inflammatory breast carcinoma: Current treatment for IBC remains similar to non-IBC which was guided by molecular subtype, including targeted therapy for HER2+ patients, chemotherapy and immunotherapy for triple negative breast cancer patients, and endocrine therapy for HR+ patients (6, 7).